Ajinomoto Co in Tokyo collaborated with its United States based consolidated subsidiary Forge Biologics, a leading CDMO in adeno associated virus development and manufacturing, to create this breakthrough formulation. Demonstration studies showed that CELLiST AAV Production Supplement 1 can improve viral vector productivity by one point three to two times when compared with conventional culture processes. These findings were presented at the Japan Society of Gene and Cell Therapy in July twenty twenty five.

This advancement directly addresses one of the most pressing challenges in the rapidly expanding gene therapy sector. As the global gene therapy market is projected to grow from seven billion United States dollars in twenty twenty two to forty six billion United States dollars by twenty thirty, efficient and scalable production tools are essential to meet the rising demand for treatments targeting both common and rare diseases.

For more than thirty years, Ajinomoto CELLiST Korea has focused on innovation in biopharmaceutical production, providing high performance CELLiST culture media optimised for CHO and HEK two nine three cell lines. The new supplement combines the Ajinomoto Group’s expertise in formulation optimisation with Forge Biologics’ experience in large scale AAV manufacturing, delivering a powerful AminoScience based solution that elevates the future of gene therapy production.

Ajinomoto CELLiST Korea will introduce CELLiST AAV Production Supplement 1 to support customers across Asia seeking higher productivity, improved scalability, and enhanced manufacturing reliability.

“We are pleased to bring CELLiST AAV Production Supplement 1 to our customers,” said President Sugiyama of Ajinomoto CELLiST Korea. “By building on the Ajinomoto Group’s strong research and development foundation, we aim to give gene therapy developers the tools they need to achieve consistent and efficient manufacturing outcomes.”

Ajinomoto CELLiST Korea remains dedicated to advancing AminoScience driven solutions that support progress in biopharmaceutical production, from monoclonal antibodies to next generation cell and gene therapies.